Is it safe to perform percutaneous treatment in acute pulmonary thrombosis?

Courtesy of Dr. Carlos Fava

Pulmonary embolismMassive and submassive pulmonary embolism (PE) has traditionally been treated with anticoagulation and catheter direct thrombolysis (CDT), but the safety and efficacy of this treatment has not been yet properly assessed.

 

The study analyzed 137 patients presenting acute PE massive or submassive. All patients received CTD associated to heparin by direct infusion or ultrasound assisted catheter. Infusion time was left to operators’ criteria.

 

Age was 59, half were men, 26% had a history of thromboembolism, 24% were diabetic, 82% had right ventricle compromise, and 12% had massive PE.

 

82% of cases presented bilateral PE, other 14% presented right pulmonary thrombosis, and the remaining 4% presented left pulmonary thrombosis. Thrombolysis was often ultrasound assisted (84%).

 

After thrombolysis, PASP decreased 19±15 mmHg and vena cava filters were implanted in 45% of patients.

 

5 patients died (all with massive PE). 13 patients presented major bleeding or vascular lesions; 4 presented bleeding (2 intracranial and 2 gastrointestinal), while other 6 required transfusions. There were no differences in thrombolysis technique.

 

Factors associated to complications were elderly age, massive PE and vena cava filter implantation.

 

In addition, a meta-analyzis of 16 studies with 860 patients presenting PE undergoing CDT (including this study) was carried out. Mean age was 60 (54-61), half of patients were men, and 21.6% presented massive PE.

 

After thrombolysis, PE decreased 15 mmHg. Major bleeding or vascular complications rate was 4.65%, intracranial bleeding was 0.35% and mortality was 3.4% (12.9% in massive PE and 0.74% in submassive).

 

Conclusion

Catheter direct thrombolysis is associated to low complications rate. Randomized studies should be carried out to assess its efficacy relative to anticoagulation alone.

 

Commentary

This analyzis –with a large number of patients− disregards the fact that it is possible to treat PE percutaneously, not just by injecting thrombolytics, but also by safely extracting thrombi.

 

Perhaps a stronger commitment to this condition might improve outcomes and help develop better devices or techniques.

 

Courtesy of Dr. Carlos Fava

 

Original Title: Safety of Catheter-Direct Thrombolysis for Massive and Submassive Pulmonary Embolism: Results for Massive and Submassive Pulmonary Embolism.

Reference: Tyler Blommer, et al. Catheterization and Cardiovasacular Intervention 2017:89:754-760.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...